Altimmune - Company & Market Research Reports

Altimmune is an immunotherapeutic biotechnology company that develops immunotherapeutic products and vaccines to address public health and biodefense needs. It offers NasoVAX, HepTcell, NasoShield and Oncosyn. The company also develops products for use in companion and commercial livestock and offers immunotherapeutic products for various disease indications. The company was founded in 1997 and is based in Gaithersburg, Maryland with operating sites in the UK and France.


Hepatitis Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Hepatitis Drug Development Pipeline Review, 2017

  • Report
  • 209 Pages
From
Prophylactic Human Vaccines - Global Strategic Business Report - Product Thumbnail Image

Prophylactic Human Vaccines - Global Strategic Business Report

  • Report
  • 358 Pages
From
Global Influenza Vaccine Market 2018-2022 - Product Thumbnail Image

Global Influenza Vaccine Market 2018-2022

  • Report
  • 113 Pages
From
Hepatitis B - Pipeline Review, H1 2018 - Product Thumbnail Image

Hepatitis B - Pipeline Review, H1 2018

  • Report
  • 365 Pages
From
Influenza A Virus, H1N1 Subtype Infections Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Influenza A Virus, H1N1 Subtype Infections Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 144 Pages
From
Influenza A Viral Infections Drug Development Pipeline Review, 2018 - Product Thumbnail Image

Influenza A Viral Infections Drug Development Pipeline Review, 2018

  • Report
  • 188 Pages
From
Swine and Avian Influenza Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Swine and Avian Influenza Drug Development Pipeline Review, 2017

  • Report
  • 119 Pages
From
Non-Small Cell Lung Cancer - Pipeline Review, H2 2017 - Product Thumbnail Image

Non-Small Cell Lung Cancer - Pipeline Review, H2 2017

  • Report
  • 2678 Pages
From
Non-Small Cell Lung Cancer - Pipeline Review, H1 2017 - Product Thumbnail Image

Non-Small Cell Lung Cancer - Pipeline Review, H1 2017

  • Report
  • 2437 Pages
From
Influenzavirus A Infections Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Influenzavirus A Infections Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 301 Pages
From
Pandemic Influenza Global Clinical Trials Review, H1, 2018 - Product Thumbnail Image

Pandemic Influenza Global Clinical Trials Review, H1, 2018

  • Clinical Trials
  • 108 Pages
From
Avian Influenza Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Avian Influenza Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 116 Pages
From
Influenza A Infections Global Clinical Trials Review, H1, 2016 - Product Thumbnail Image

Influenza A Infections Global Clinical Trials Review, H1, 2016

  • Clinical Trials
  • 237 Pages
From
Mosquito-borne Diseases Drug Development Pipeline Review, 2018 - Product Thumbnail Image

Mosquito-borne Diseases Drug Development Pipeline Review, 2018

  • Report
  • 142 Pages
From
Malaria - Pipeline Review, H1 2018 - Product Thumbnail Image

Malaria - Pipeline Review, H1 2018

  • Report
  • 346 Pages
From
Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H1 2018 - Product Thumbnail Image

Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H1 2018

  • Report
  • 149 Pages
From
Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2018 - Product Thumbnail Image

Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2018

  • Report
  • 222 Pages
From
Anthrax - Pipeline Review, H1 2018 - Product Thumbnail Image

Anthrax - Pipeline Review, H1 2018

  • Report
  • 109 Pages
From
Anthrax - Pipeline Review, H2 2017 - Product Thumbnail Image

Anthrax - Pipeline Review, H2 2017

  • Report
  • 142 Pages
From
Anti-infective Drugs Market Global Briefing 2018 - Product Thumbnail Image

Anti-infective Drugs Market Global Briefing 2018

  • Report
  • 35 Pages
From
Loading Indicator
adroll